Cargando…
Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2
INTRODUCTION: A second generation of prophylactic human papillomavirus (HPV) vaccines based on the minor capsid protein L2 has entered clinical trials as promising alternative to meet the gaps left out by the current vaccines concerning type-restricted protection, high costs and low penetrance in im...
Autores principales: | Mariz, Filipe Colaco, Putzker, Kerstin, Sehr, Peter, Müller, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663238/ https://www.ncbi.nlm.nih.gov/pubmed/38022617 http://dx.doi.org/10.3389/fimmu.2023.1272018 |
Ejemplares similares
-
High-Throughput Pseudovirion-Based Neutralization Assay for Analysis of Natural and Vaccine-Induced Antibodies against Human Papillomaviruses
por: Sehr, Peter, et al.
Publicado: (2013) -
Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles
por: Yang, Fan, et al.
Publicado: (2020) -
Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31
por: Fleury, M. J. J., et al.
Publicado: (2006) -
Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33
por: Roth, Stefanie D, et al.
Publicado: (2006) -
Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
por: Mariz, Filipe Colaço, et al.
Publicado: (2020)